COVID-19 Vaccine Effectiveness Data 2025
Latest clinical studies confirm continued strong protection against severe illness from current COVID-19 vaccines. New data shows effectiveness rates against emerging variants and updated booster recommendations for different population groups.
Key Findings
Vaccine Performance Comparison
2025 Vaccine Formulations
Pfizer-BioNTech
Updated 2025 Formula
Moderna
mRNA-1273.232
Novavax
NVX-CoV2373 2025
Effectiveness Against Current Variants
Protection Rates by Variant
| Variant | Status | Pfizer | Moderna | Novavax |
|---|---|---|---|---|
NB.1.8.1 Slight reduction from previous variants but maintains strong protection | Rapidly spreading | 85% | 87% | 79% |
KP.3.1.1 Excellent protection maintained across all vaccines | Previously dominant | 89% | 91% | 84% |
XEC Good protection; recombinant nature requires monitoring | Growing globally | 82% | 85% | 77% |
LP.8.1 Strong protection across all age groups | Stable | 88% | 90% | 82% |
Supporting Clinical Studies
Multi-Country Effectiveness Study
WHO Global Vaccine Effectiveness Network2.4 million
6 months
87% reduction in severe illness across all variants
Real-World Protection Analysis
CDC Vaccine Effectiveness Surveillance1.8 million
12 months
Booster doses restore protection to >90% against hospitalization
Variant-Specific Immunity Study
European Centre for Disease Prevention850,000
8 months
Cross-protection maintained against emerging variants
Updated Booster Recommendations
Population-Specific Guidelines
Adults 65+
High PriorityEvery 6 months
Age-related immune decline requires more frequent boosting
Immunocompromised
Very High PriorityEvery 4-6 months
Reduced immune response necessitates frequent updates
Healthcare Workers
High PriorityEvery 6-8 months
High exposure risk and need to protect patients
General Adult Population
Moderate PriorityAnnually
Annual boosters provide adequate protection for most adults